

## REMARKS

The above preliminary amendment is made to insert color drawings into the application, to remove multiple dependencies from claims 25-27, 31, 34, and 36, and to add new claims 38-53.

Attached hereto is a marked-up version of the changes made to the claims by the current amendment. The attached page is captioned "Marked-up Copy".

Applicants respectfully request that the preliminary amendment described herein be entered into the record prior to calculation of the filing fee and prior to examination and consideration of the above-identified application.


If a telephone conference would be helpful in resolving any issues concerning this communication, please contact Applicants' primary attorney-of record, Brian H. Batzli (Reg. No. 32,960), at (612) 336.4755.

Respectfully submitted,

MERCHANT & GOULD P.C.  
P.O. Box 2903  
Minneapolis, Minnesota 55402-0903  
(612) 332-5300

Dated: 27 June 2003


By

  
Brian H. Batzli  
Reg. No. 32,960

BHB:hjh


MARKED-UP COPY

25. A composition according to claim 1, [6 or 17] comprising about 0.001% - 5% glycoalkaloids.
26. A composition according to claim 1, [6 or 17] comprising about 10% glycoalkaloids.
27. A pharmaceutical composition comprising a composition of claim 1, [6 or 17] and a pharmaceutically acceptable carrier.
31. A method of treating cancer in a subject comprising the step of administering to the subject an effective amount of a composition [of claim 1, 6 or 17] comprising at least two glycoalkaloids of formula I:



wherein: either one or both of the dotted lines represents a double bond, and the other a single bond, or both represent single bonds;

A: represents a radical selected from the following radicals of general formulae (II) to (V):



each of R<sup>1</sup> is a radical separately selected from the group consisting of hydrogen, amino, oxo and OR<sup>4</sup>;

each of R<sup>2</sup> is a radical separately selected from the group consisting of hydrogen, amino and OR<sup>4</sup>;


each of R<sup>3</sup> is a radical separately selected from the group consisting of hydrogen, carbohydrate and a carbohydrate derivative;

“X” is a radical selected from the group comprising –CH<sub>2</sub>–, –O– and –NH<sub>2</sub>–; and

wherein the compound includes at least one R<sup>4</sup> group that is a carbohydrate or a derivative thereof selected from the group comprising glyceric aldehyde, glycerose, erythrose, threose, ribose, arabinose, xylose, lyxose, altrose, allose, gulose, mannose, glucose, idose, galactose, talose, rhamnose, dihydroxyactone, erythrulose, ribulose, xylulose, psicose, fructose, sorbose, tagatose, and other hexoses, heptoses, octoses, nanoses, decoses, deoxysugars with branched chains, (e.g. apiose, hamamelose, streptose, cordycepose, mycarose and cladinose), compounds wherein the aldehyde, ketone or hydroxyl groups have been substituted (e.g. N-acetyl, acetyl, methyl, replacement of CH<sub>2</sub>OH), sugar alcohols, sugar acids, benzimidazoles, the enol salts of the carbohydrates, saccharinic acids, sugar phosphates;


wherein the ratio of said glycoalkaloids is between 6:1 and 1:6 and on the proviso that when the glycoalkaloids are solamargine and solasonine and they are present in a 1:1 ratio the solamargine and solasonine are isolated, or a pharmaceutical composition of claim 27.

32. A method of treating psoriasis in a subject comprising the step of administering to the subject an effective amount of a composition [of claim 1, 6 or 17] comprising the step of administering to the subject an effective amount of a composition comprising at least two glycoalkaloids of formula I:



wherein: either one or both of the dotted lines represents a double bond, and the other a single bond, or both represent single bonds;

A: represents a radical selected from the following radicals of general formulae (II) to (V):



each of  $R^1$  is a radical separately selected from the group consisting of hydrogen, amino, oxo and  $OR^4$ ;

each of  $R^2$  is a radical separately selected from the group consisting of hydrogen, amino and  $OR^4$ ;


each of R<sup>3</sup> is a radical separately selected from the group consisting of hydrogen, carbohydrate and a carbohydrate derivative;

“X” is a radical selected from the group comprising –CH<sub>2</sub>–, –O– and –NH<sub>2</sub>–; and

wherein the compound includes at least one R<sup>4</sup> group that is a carbohydrate or a derivative thereof selected from the group comprising glyceric aldehyde, glycerose, erythrose, threose, ribose, arabinose, xylose, lyxose, altrose, allose, gulose, mannose, glucose, idose, galactose, talose, rhamnose, dihydroxyactone, erythrulose, ribulose, xylulose, psicose, fructose, sorbose, tagatose, and other hexoses, heptoses, octoses, nanoses, decoses, deoxysugars with branched chains, (e.g. apiose, hamamelose, streptose, cordycepose, mycarose and cladinoses), compounds wherein the aldehyde, ketone or hydroxyl groups have been substituted (e.g. N-acetyl, acetyl, methyl, replacement of CH<sub>2</sub>OH), sugar alcohols, sugar acids, benzimidazoles, the enol salts of the carbohydrates, saccharinic acids, sugar phosphates;


wherein the ratio of said glycoalkaloids is between 6:1 and 1:6 and on the proviso that when the glycoalkaloids are solamargine and solasonine and they are present in a 1:1 ratio the solamargine and solasonine are isolated, or pharmaceutical composition of claim 27.

33. A method of treating or abnormal cell growth in a patient comprising the step of administering an effective amount of a composition [of claim 1, 6 or 17] comprising at least two glycoalkaloids of formula I:



wherein: either one or both of the dotted lines represents a double bond, and the other a single bond, or both represent single bonds;

A: represents a radical selected from the following radicals of general formulae (II) to (V):



each of  $R^1$  is a radical separately selected from the group consisting of hydrogen, amino, oxo and  $OR^4$ ;

each of  $R^2$  is a radical separately selected from the group consisting of hydrogen, amino and  $OR^4$ ;


each of  $R^3$  is a radical separately selected from the group consisting of hydrogen, carbohydrate and a carbohydrate derivative;

“X” is a radical selected from the group comprising  $-CH_2-$ ,  $-O-$  and  $-NH_2-$ ; and

wherein the compound includes at least one  $R^4$  group that is a carbohydrate or a derivative thereof selected from the group comprising glyceric aldehyde, glycerose, erythrose, threose, ribose, arabinose, xylose, lyxose, altrose, allose, gulose, mannose, glucose, idose, galactose, talose, rhamnose, dihydroxyactone, erythrulose, ribulose, xylulose, psicose, fructose, sorbose, tagatose, and other hexoses, heptoses, octoses, nanoses, decoses, deoxysugars with branched chains, (e.g. apiose, hamamelose, streptose, cordycepose, mycarose and cladinoses), compounds wherein the aldehyde, ketone or hydroxyl groups have been substituted (e.g. N-acetyl, acetyl, methyl, replacement of  $CH_2OH$ ), sugar alcohols, sugar acids, benzimidazoles, the enol salts of the carbohydrates, saccharinic acids, sugar phosphates;


wherein the ratio of said glycoalkaloids is between 6:1 and 1:6 and on the proviso that when the glycoalkaloids are solamargine and solasonine and they are present in a 1:1 ratio the solamargine and solasonine are isolated, or pharmaceutical composition of claim 27 to the patient.

34. A method of diagnosing abnormal cell growth in a subject comprising the step of applying a composition [of claim 1, 6 or 17] comprising at least two glycoalkaloids of formula I:



wherein: either one or both of the dotted lines represents a double bond, and the other a single bond, or both represent single bonds;

A: represents a radical selected from the following radicals of general formulae (II) to (V):



each of R<sup>1</sup> is a radical separately selected from the group consisting of hydrogen, amino, oxo and OR<sup>4</sup>;

each of R<sup>2</sup> is a radical separately selected from the group consisting of hydrogen, amino and OR<sup>4</sup>;

each of R<sup>3</sup> is a radical separately selected from the group consisting of hydrogen, carbohydrate and a carbohydrate derivative;

“X” is a radical selected from the group comprising –CH<sub>2</sub>–, –O– and –NH<sub>2</sub>–; and

wherein the compound includes at least one R<sup>4</sup> group that is a carbohydrate or a derivative thereof selected from the group comprising glyceric aldehyde, glycerose, erythrose, threose, ribose, arabinose, xylose, lyxose, altrose, allose, gulose, mannose, glucose, idose, galactose, talose, rhamnose, dihydroxyactone, erythrulose, ribulose, xylulose, psicose, fructose, sorbose, tagatose, and other hexoses, heptoses, octoses, nanoses, decoses, deoxysugars with branched chains, (e.g. apiose, hamamelose, streptose, cordycepose, mycarose and cladinoses), compounds wherein the aldehyde, ketone or hydroxyl groups have been substituted (e.g. N-acetyl, acetyl, methyl, replacement of CH<sub>2</sub>OH), sugar alcohols, sugar acids, benzimidazoles, the enol salts of the carbohydrates, saccharinic acids, sugar phosphates;

wherein the ratio of said glycoalkaloids is between 6:1 and 1:6 and on the proviso that when the glycoalkaloids are solamargine and solasonine and they are present in a 1:1 ratio the solamargine and solasonine are isolated, or pharmaceutical composition of claim 27 to a test area on said subject and then monitoring said test area for inflammation.

36. A composition of claim 1, [6 or 17] further comprising a detectable label.

